TGFB1 and colorectal carcinoma: As a result of the simultaneous L1-CAM and TGF-β targeting, the developed encapsulated DNPs-LY carrying galunisertib 2.5 μM inhibited the migration of CRC cells with higher efficiency than free drug at an equal concentration (Figure 5e) [35].